Genmab | Sustainability Performance
Genmab A/S engages in the development of differentiated antibody therapeutics for the treatment of cancer, utilizing advanced proprietary technology to create innovative products.
1999
Denmark
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#166
Overallⓘ#6
in Denmarkⓘ#2
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsDigital emissionsEnergy consumptionNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Laggard
Leading
Leading
Intensity
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Industry Benchmark
51.4
B/M 128.6
Powered by illuminem and GIST Impact
Controversy level
- Genmab's cancer drug Darzalex (via partner J&J) faced criticism over pricing making the treatment unaffordable for some patient populations.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.